Vanguard Personalized Indexing Management
CRSP icon

Vanguard Personalized Indexing Management’s CRISPR Therapeutics CRSP Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,073
Closed -$241K – 2269
2026
Q1 		$241K Buy
+5,073
New +$268K ﹤0.01% 1723
2024
Q3 		– Sell
-4,167
Closed -$225K – 1786
2024
Q2 		$225K Buy
4,167
+486
+13% +$28.1K ﹤0.01% 1406
2024
Q1 		$251K Sell
3,681
-546
-13% -$39.1K 0.01% 1345
2023
Q4 		$265K Buy
+4,227
New +$234K 0.01% 1287
2021
Q3 		– Sell
-1,301
Closed -$211K – 1000
2021
Q2 		$211K Buy
+1,301
New +$158K 0.02% 877

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Personalized Indexing Management's CRSP Position: Q2 2026 in Review

Vanguard Personalized Indexing Management sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 5,073 shares — an estimated $241K sold.

Vanguard Personalized Indexing Management first reported a position in CRSP in Q2 2021 and held it in 5 quarters. The position peaked at $265K in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Vanguard Personalized Indexing Management reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 5,073 CRISPR Therapeutics shares in Q2 2026, an estimated $241K.
  • Vanguard Personalized Indexing Management first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 5 quarters.
  • Vanguard Personalized Indexing Management's CRISPR Therapeutics position peaked at $265K in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.